Clinical trials: Neoplasm, Uterine
Cervical Cancer, Transgender Persons
Gynecology Beyond Gender: Cervical Cancer Screening in Transgender Men in France
In France, cervical cancer screening is the subject of a national screening programme organized for all asymptomatic individuals aged 25 to 65 years with a cervix.
- Conditions
- Cervical Cancer, Transgender Persons, Health Services for Transgender Persons
- Trial name
- GYDECAT (NCT05924217)
- Testing
- Survey questionnaire
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Uterine Leiomyomas
Bleeding Control Methods in Open Myomectomy
Excessive intraoperative bleeding remains a major challenge during open myomectomy and may lead to postoperative anemia and increased morbidity.
- Trial name
- NCT07553091
- Testing
- Tourniquet application, Uterine artery bulldog clamp
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Yuzuncu Yil University
Prostate Cancer, Cervical Cancer
Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)
The accuracy of radiotherapy can be increased by correcting for geometric uncertainties and changes between radiotherapy fractions.
- Conditions
- Prostate Cancer, Cervical Cancer, Bladder Cancer, Lung Cancer
- Trial name
- FASCINATE (NCT06691776)
- Testing
- online CBCT-guided adaptive radiation therapy using a new software
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Endometrial Neoplasms, Ovarian Neoplasms
STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer
The purpose of this study is to determine whether or not there are more complications in the extraperitoneal compared with the transperitoneal approach for laparoscopic aortic lymphadenectomy for the surgical staging of…
- Trial name
- STELLA-2 (NCT02676726)
- Testing
- Extraperitoneal Laparoscopic aortic lymphadenectomy, Transperitoneal Laparoscopic aortic lymphadenectomy
- Where
- Spain
- Volunteers
- 208 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Cervical Cancer, Screening
Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs
Artificial intelligence (AI) is fast gaining reputation as a highly promising solution for cervical cancer screening. AI-based detection of cervical neoplasias is named automated visual exam (AVE) by the National Cancer…
- Trial name
- EASTER (NCT06042543)
- Testing
- Screening with HPV test
- Where
- 2 sites in United States, Zimbabwe
- Volunteers
- 3,200 people
- Sponsor
- International Agency for Research on Cancer
Cervical Cancer
The Effect of the Program on the Awareness of Roma Women on Cervical Cancer
This study, which is designed according to the experimental model with randomized pre-test and post-test control group, will be carried out with Roman women who apply to Yavuz Selim Family Health Center in Samsun province, Canik…
- Trial name
- NCT04756440
- Testing
- Education Program and Music Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ondokuz Mayıs University
Cervical Cancer
The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients with Advanced, Non-Resectable HPV-Positive Cervical Cancer
- Trial name
- NCT03444376
- Testing
- GX-188E, KEYTRUDA®
- Where
- 9 sites in South Korea
- Volunteers
- 65 people
- Sponsor
- Genexine, Inc.
Uterine Fibroids
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
PK of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.
- Trial name
- NCT00683917
- Testing
- Proellex 25 mg, Proellex 50 mg, Lupron Depot
- Where
- 4 sites in United States, Mexico
- Volunteers
- 10 people
- Sponsor
- Repros Therapeutics Inc.
Cervical Cancers
Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer
Cervical cancer ranks fourth globally in both incidence and mortality rates, making early diagnosis and treatment of great significance. For early-stage cervical cancer, surgery remains the primary treatment approach.
- Trial name
- NCT07130240
- Testing
- Neoadjuvant Chemotherapy Combined with Immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Uterine Fibroid, Vaginal Bleeding.
Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids
The purpose of this study is to evaluate the effect of daily dosage of vaginally mifepristone on reduction of uterine fibroids size and the symptoms associated with uterine fibroids.
- Trial name
- NCT00881140
- Testing
- mifepristone vaginal tablets
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- BioPro Medical Ltd
Endometrial Cancer
Activity and Cancer Survivorship Exercise Pilot
This early phase I clinical trial measures the changes in functional fitness following home-based comprehensive exercise program in patients who have endometrial cancer who have completed treatment.
- Trial name
- NCT07283029
- Testing
- Functional fitness following home-based comprehensive exercise program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Iowa
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying the side effects of gemcitabine and to see how well it works in treating patients with recurrent or persistent endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
- Trial name
- NCT00820898
- Testing
- Gemcitabine Hydrochloride
- Where
- 20 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Cancer
Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00085332
- Testing
- docetaxel
- Where
- 75 sites in United States, Australia and 3 more
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer, Endometrial Cancer
Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial…
- Trial name
- Clovis-001 (NCT03476798)
- Testing
- Rucaparib, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Oklahoma
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable
- Trial name
- NCT05572684
- Testing
- NC410, pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 97 people
- Sponsor
- NextCure, Inc.
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- TG-003 (NCT00596258)
- Testing
- A-007
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Tigris Pharmaceuticals
Endometrial Cancer
Uterine Manipulator in Endometrial Cancer Surgery: Pro MUCEI Study
The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use…
- Trial name
- proMUCEI (NCT05242276)
- Testing
- USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMY
- Where
- Spain
- Volunteers
- 1,200 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Cervical Cancer
Characterization of Immunosuppressive Signing of Cervical Cancer
Infection with Human Papillomavirus high-risk Human (HR-HPV) is the main factor of risk of cancer of the cervix. Recent studies show that cancers linked to infection with HR-HPV are associated with immunosuppression and lack of T…
- Trial name
- Xac03 (NCT02875990)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cervical Cancer, Breast Cancer
Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function
In this study proposal, the investigators will extend their previous studies and examine the kinetic cytotoxic activity with concordant expression of inhibitory natural killer (NK) receptors (iNKR) on activated T cells.
- Conditions
- Cervical Cancer, Breast Cancer, Endometrial Cancer, Cancer
- Trial name
- NCT00173290
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Recurrent Uterine Corpus Carcinoma
Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Phase II trial to study the effectiveness of gefitinib in treating patients who have persistent or recurrent endometrial cancer.
- Trial name
- NCT00027690
- Testing
- Gefitinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.